Serum pentosidine, an advanced glycation end product, indicates poor outcomes after acute ischemic stroke

Journal of Stroke and Cerebrovascular Diseases

Volumn 21, Issue 5, 2012, Pages 386-390

  Ikeda, Toshiki ^a,b   Maruyama, Keisuke ^b   Ito, Nobuyuki ^a,b   Utagawa, Akira ^a,c   Nagane, Motoo ^b   Shiokawa, Yoshiaki ^b  

^a Akiru Municipal Medical Center   (Japan)

^b KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Advanced glycation end products; ischemic stroke; outcome; pentosidine

Indexed keywords

CREATININE; PENTOSIDINE;

AGED; ARTICLE; BRAIN EMBOLISM; BRAIN ISCHEMIA; FEMALE; HOSPITALIZATION; HUMAN; LACUNAR STROKE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANKIN SCALE; RISK FACTOR; STROKE PATIENT; THROMBOSIS; UNIVARIATE ANALYSIS;

AGED; ARGININE; BIOLOGICAL MARKERS; COHORT STUDIES; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HOSPITALIZATION; HUMANS; LOGISTIC MODELS; LYSINE; MALE; PROGNOSIS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; STROKE;

EID: 84862883893     PISSN: 10523057     EISSN: 15328511     Source Type: Journal    
DOI: 10.1016/j.jstrokecerebrovasdis.2010.10.004     Document Type: Article

References (37)

1. Donnan GA, Fisher M, Macleod M, et al. Stroke. Lancet 2008;371:1612-1623. (Pubitemid 351626845)
2. Nakase T, Sato M, Yamazaki T, et al. Inflammatory makers observed in the acute phase of ischemic stroke: A possible indicator of severity and prognosis. Jpn J Stroke 2006;28:360-366.
3. Traystman RJ, Kirsch JR, Koehler RC. Oxygen radical mechanisms of brain injury following ischemia and reperfusion. J Appl Physiol 1991;71:1185-1195.
4. Castillo J, Rodriguez I. Biochemical changes and inflammatory response as makers for brain ischemia: Molecular makers of diagnostic utility and prognosis in human clinical practice. Cerebrovasc Dis 2004;17:7-18. (Pubitemid 38032517)
5. Liu H, Uno M, Kitazato KT, et al. Peripheral oxidative biomarkers constitute a valuable indicator of the severity of oxidative brain damage in acute cerebral infarction. Brain Res 2004;1025:43-50. (Pubitemid 39349524)
6. Dyer DG, Dunn JA, Thorpe SR, et al. Accumulation of Maillard reaction products in skin collagen in diabetes and aging. J Clin Invest 1993;91:2463-2469. (Pubitemid 23182497)
7. Beisswenger PJ, Moore LL, Brinck-Johnsen T, et al. Increased collagen-linked pentosidine levels and advanced glycosylation end products in early diabetic nephropathy. J Clin Invest 1993;92:212-217. (Pubitemid 23208998)
8. Odetti P, Fogarty J, Sell DR, et al. Chromatographic quantitation of plasma and erythrocyte pentosidine in diabetic and uremic subjects. Diabetes 1992;41:153-159.
9. Miyata T, Ueda Y, Shinzato T, et al. Accumulation of albumin-linked and free-form pentosidine in the circulation of uremic patients with end-stage renal failure: Renal implications in the pathophysiology of pentosidine. J Am Soc Nephrol 1996;7:1198-1206. (Pubitemid 27468273)
10. Miyata T, Ueda Y, Yoshida A, et al. Clearance of pentosidine, an advanced glycation end product, by different modalities of renal replacement therapy. Kidney Int 1997;51:880-887. (Pubitemid 27157977)
11. Koyama H, Yamamoto H, Nishizawa Y. RAGE and soluble RAGE: Potential therapeutic targets for cardiovascular diseases. Mol Med 2007;13:625-635. (Pubitemid 350228723)
12. Koyama H, Shoji T, Fukumoto S, et al. Low circulating endogenous secretory receptor for AGEs predicts cardiovascular mortality in patients with end-stage renal disease. Arterioscler Thromb Vasc Biol 2007;27:147-153. (Pubitemid 46360392)
13. Shoji T, Koyama H, Morioka T, et al. Receptor for advanced glycation end products is involved in impaired angiogenic response in diabetes. Diabetes 2006;55:2245-2255. (Pubitemid 44743621)
14. Koyama H, Shoji T, Yokoyama H, et al. Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol 2005;25:2587-2593. (Pubitemid 43732283)
15. Miyata T, Ueda Y, Horie K, et al. Renal catabolism of advanced glycation end products: The fate of pentosidine. Kidney Int 1998;53:416-422. (Pubitemid 28097858)
16. Takahashi M, Suzuki M, Kushida K, et al. Relationship between pentosidine levels in serum and urine and activity in rheumatoid arthritis. Br J Rheumatol 1997;36:637-642.
17. Rodriguez-Garcia J, Requena JR, Rodriguez-Segada S. Increased concentrations of serum pentosidine in rheumatoid arthritis. Clin Chem 1998;44:250-255. (Pubitemid 28087720)
18. Hein GE, Kohler M, Oelzner P, et al. The advanced glycation end product pentosidine correlates to IL-6 and other relevant inflammatory makers in rheumatoid arthritis. Rheumatol Int 2005;26:137-141. (Pubitemid 41779823)
19. Koyama Y, Takeishi Y, Arimoto T, et al. High serum level of pentosidine, an advanced glycation end product (AGE), is a risk factor of patients with heart failure. J Card Fail 2007;13:199-206. (Pubitemid 46590033)
20. Lyden PD, Lu M, Levine SR, et al, NINDS rtPA Stroke Study Group. A modified National Institutes of Health Stroke Scale for use in stroke clinical trials: Preliminary reliability and validity. Stroke 2001;32:1310-1317.
21. Rankin J. Cerebral vascular accidents in patients over 60. II. Prognosis. Scott Med J 1957;2:200-215.
22. van Swieten JC, Koudstaal PJ, Visser MC, et al. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988;19:604-607.
23. Yamaguchi T, Mori E, Minematsu K, et al Japan Alteplase Clinical Trial (J-ACT) Group. Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset: Japan Alteplase Clinical Trial (J-ACT). Stroke 2006;37:1810-1815. (Pubitemid 44297734)
24. Ohnuki Y, Nagano R, Takizawa S, et al. Advanced glycation end products in patients with cerebral infarction. Intern Med 2009;48:587-591.
25. Park HY, Yun KH, Park DS. Levels of soluble receptor for advanced glycation end products in acute ischemic stroke without a source of cardioembolism. J Clin Neurol 2009;5:126-132.
26. Kannel WB, Wolf PA, McGee DL, et al. Systolic blood pressure, arterial rigidity, and risk of stroke. The Framingham Study. JAMA 1981;245:1225-1229. (Pubitemid 11113849)
27. Tanaka H, Ueda Y, Hayashi M, et al. Risk factors for cerebral hemorrhage and cerebral infarction in a Japanese rural community. Stroke 1982;13:62-73. (Pubitemid 12219051)
28. PROGRESS Collaborative Group. Randomized trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033-1041.
29. Abbot RD, Donahue RP, MacMahon SW, et al. Diabetes and risk of stroke. The Honolulu Heart Program. JAMA 1987;257:949-952. (Pubitemid 17024388)
30. Iso H, Jacobs DR Jr,Wentworth D, et al. Serum cholesterol levels and six year mortality from stroke in 350,997 men screened for the multiple risk factor intervention trial. N Engl J Med 1989;320:904-910. (Pubitemid 19101595)
31. Paciaroni M, Arnold P, Van Melle G, et al. Severe disability at hospital discharge in ischemic stroke survivors. Eur Neurol 2000;43:30-34. (Pubitemid 30045320)
32. Olsen TS, Christensen RH, Kammersgaard LP, et al. Higher total serum cholesterol levels are associated with less severe strokes and lower all-cause mortality: Ten-year follow-up of ischemic strokes in the Copenhagen Stroke Study. Stroke 2007;38:2646-2651. (Pubitemid 47493998)
33. Wautier JL, Schmidt AM. Protein glycation: A firm link to endotherial cell dysfunction. Circ Res 2004;95:233-238. (Pubitemid 39056283)
34. Basta G, Schmidt AM, De Caterina R. Advanced glycation end products and vascular inflammation: Implications for accelerated atherosclerosis in diabetes. Cardiovasc Res 2004;63:582-592. (Pubitemid 39078671)
35. Yamagishi S, Yonekura H, Yamamoto Y, et al. Advanced glycation endproducts-driven angiogenesis in vitro. Induction of the growth and tube formation of human microvascular endothelial cells through autocrine vascular endothelial growth factor. J Biol Chem 1997;272: 8723-8730. (Pubitemid 27147841)
36. Zinmmerman GA, Meistrell M, Bloom O, et al. Neurotoxicity of advanced glycation endproducts during focal stroke and neuroprotective effects of aminoguanidine. Proc Natl Acad Sci U S A 1995;92:3744-3748.
37. Takizawa S, Izuhara Y, Kitao Y, et al. A novel inhibitor of advanced glycation and endoplasmic reticulum stress reduces infarct volume in rat focal cerebral ischemia. Brain Res 2007;5:124-137.